High-dose glycine added to olanzapine and risperidone for the treatment of schizophrenia
The DOI matches its Crossref record; 47 of the 48 references it cites were found in a registry or an index.
Abstract
Background Clinical trials indicate that glycine site agonists of the N-methyl-D-aspartate (NMDA) receptors may reduce negative and cognitive symptoms in treatment-resistant schizophrenia when used as adjuvants to conventional antipsychotics but possibly not to clozapine. In this study, we assessed whether high-dose glycine may also be therapeutically beneficial when added to olanzapine and risperidone treatment.Methods Seventeen olanzapine- or risperidone-treated schizophrenia patients participated in a double-blind, placebo-controlled, 6-week crossover treatment trial with.8 g/kg/day glycine added to their ongoing antipsychotic medication. Clinical assessments were performed biweekly throughout the study. Clinical laboratory parameters and amino acid serum levels were monitored.Results Glycine treatment was well tolerated and resulted in a significant (p <.0001) 23% +/- 8% reduction in negative symptoms. Significant improvements were also registered in cognitive and positive symptoms. The negative symptoms improvement remained significant even following covariation for changes in other symptom clusters and extrapyramidal side effects. High posttreatment glycine serum levels significantly predicted (r =.60) clinical response.Conclusions These findings indicate that the efficacy of olanzapine and risperidone may be augmented using high-dose adjuvant glycine treatment and suggest that these atypical antipsychotics may affect NMDA receptor-mediated neurotransmission differently than clozapine.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“some studies showing modest benefits (Heresco-Levy et al., 2004”
From Neuronal Dynamics and Neuropsychiatric Disorders: Toward a Translational Paradigm for Dysfunctional Large-Scale Networks (2012) · cites this paper as Heresco-Levy et al., 2004
In the citing paper
“Evidence on the efficacy of this approach is still sparse with some studies showing modest benefits (Heresco-Levy et al., 2004”
From Neuronal Dynamics and Neuropsychiatric Disorders: Toward a Translational Paradigm for Dysfunctional Large-Scale Networks (2012) · cites this paper as Heresco-Levy et al., 2004
Citations
Cites
Diagnostic and Statistical Manual of Mental Disorders
Williams, J. B. W., & First, M. (2013) · Encyclopedia of Social Work · doi:10.1093/acrefore/9780199975839.013.104 · Cited by 109,519
The Brief Psychiatric Rating Scale.
Overall, J. E., & Gorham, D. R. (1962) · Psychological Reports · doi:10.2466/pr0.1962.10.3.799 · Cited by 11,090
(1976) · Medical Entomology and Zoology · Cited by 8,899
Krystal, J. H. (1994) · Archives of General Psychiatry · doi:10.1001/archpsyc.1994.03950030035004 · Cited by 3,330
A RATING SCALE FOR EXTRAPYRAMIDAL SIDE EFFECTS
SIMPSON, G. M., B., M., B., G., ANGUS, J. W. S., P., F. R. C., & M., D. P. (1970) · Acta Psychiatrica Scandinavica · doi:10.1111/j.1600-0447.1970.tb02066.x · Cited by 3,264
Glycine potentiates the NMDA response in cultured mouse brain neurons
Johnson, J. W., & Ascher, P. (1987) · Nature · doi:10.1038/325529a0 · Cited by 3,139
Psychopharmacology: The Fourth Generation of Progress
Bloom, F. E., & Kupfer, D. J. (1995) · Medical Entomology and Zoology · Cited by 2,985
Recent advances in the phencyclidine model of schizophrenia
(1991) · American Journal of Psychiatry · doi:10.1176/ajp.148.10.1301 · Cited by 2,904
Self-citationPsychopharmacology: The Fourth Generation of Progress
Brophy, J. J. (1995) · JAMA: The Journal of the American Medical Association · doi:10.1001/jama.1995.03530220079046 · Cited by 1,582
Requirement for Glycine in Activation of NMDA-Receptors Expressed in Xenopus Oocytes
Kleckner, N. W., & Dingledine, R. (1988) · Science · doi:10.1126/science.2841759 · Cited by 1,422
Research works printed but not linked: 4
- Barbeau, 1974, Preliminary study of glycine administration in patients with spasticity, Neurology, 24, 392
- Danysz, 1998, Glycine and N-methyl-D-aspartate receptors, Pharmacol Rev, 50, 597
- Kostakow, 1933, Glycocoll treatment of progressive muscular dystrophy, Deutsch Arch Klin Med, 175, 25
- Milhorat, 1933, Treatment of progressive muscular dystrophy and similar muscular disturbances with glycine, Deutsch Arch Klin Med, 174, 487
Cited by
D-Alanine Added to Antipsychotics for the Treatment of Schizophrenia
Tsai, G. E., Yang, P., Chang, Y.-C., & Chong, M.-Y. (2006) · Biological Psychiatry · doi:10.1016/j.biopsych.2005.06.032 · Cited by 674
Javitt, D. C. (2007) · International Review of Neurobiology · doi:10.1016/s0074-7742(06)78003-5 · Cited by 560
Self-citationGlutamate as a therapeutic target in psychiatric disorders
Javitt, D. C. (2004) · Molecular Psychiatry · doi:10.1038/sj.mp.4001551 · Cited by 524
Self-citationUhlhaas, P. J., & Singer, W. (2012) · Neuron · doi:10.1016/j.neuron.2012.09.004 · Cited by 512
Buchanan, R. W., Javitt, D. C., Marder, S. R., Schooler, N. R., Gold, J. M., McMahon, R. P., Heresco-Levy, U., & Carpenter, W. T. (2007) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2007.06081358 · Cited by 419
Self-citation
Metadata
- Authors
- Heresco-Levy, U., Ermilov, M., Lichtenberg, P., Bar, G., & Javitt, D. C.
- Affiliations
- Hebrew University of Jerusalem (IL)
- Herzog Hospital (IL)
- Nathan Kline Institute for Psychiatric Research (US)
- ORCID
- Javitt, Daniel C
- Venue
- Biological Psychiatry
- Publisher
- Elsevier BV
- Published
- 2004-01
- Volume
- 55
- Issue
- 2
- Pages
- 165-171
- ISSN
- 0006-3223 (ISSN-L)
- OpenAlex
- W2068898125
- Cited by
- 222
- References
- 48
- Citations by year
- 2026: 3 · 2025: 7 · 2024: 5 · 2023: 6 · 2022: 7 · 2021: 10 · 2020: 1 · 2019: 7 · 2018: 6 · 2017: 11 · 2016: 12 · 2015: 10 · 2014: 8 · 2013: 11 · 2012: 10
- FWCI
- 12.31
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.elsevier.com/tdm/userlicense/1.0/ (tdm)
- Locations
- Biological Psychiatry (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Psychiatry and Mental health › Schizophrenia research and treatment
- Health Sciences › Medicine › Pharmacology (medical) › Treatment of Major Depression
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Biochemistry › Amino Acid Enzymes and Metabolism
- Keywords
- glycine, olanzapine, risperidone, schizophrenia, NMDA receptor agonist, negative symptoms, cognitive symptoms, positive symptoms, atypical antipsychotics, adjuvant therapy, treatment response prediction, extrapyramidal symptoms
- MeSH terms
- Olanzapine, Adult, Behavioral Symptoms, Benzodiazepines, Dose-Response Relationship, Drug, Double-Blind Method, Drug Therapy, Combination, Female, Glycine, Humans, Male, Middle Aged, Pirenzepine, Schizophrenia, Serine, Time Factors, Antipsychotic Agents, Multivariate Analysis, Treatment Outcome, Cross-Over Studies, Risperidone
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: High-dose glycine added to olanzapine and risperidone for the treatment of schizophrenia. https://app.cochat.ai/papers/10.1016/s0006-3223(03)00707-8
- The paper
- Heresco-Levy, U., Ermilov, M., Lichtenberg, P., Bar, G., & Javitt, D. C. (2004). High-dose glycine added to olanzapine and risperidone for the treatment of schizophrenia. Biological Psychiatry. https://doi.org/10.1016/s0006-3223(03)00707-8
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.